BioSpace News Archive

Study 218 compares 18 mg and 14 mg starting doses of LENVIMA plus 5 mg everolimus in patients with clear-cell RCC following prior anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted

Results of AscenD-LB Phase 2 clinical study demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB)

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

A knowledgeable patient is an empowered patient, and the ability to understand and proactively manage a health challenge can help improve quality of life, according to Robyn Wiesel, associate director of Public & Patient Education at Hospital for Special Surgery.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, reported that investigators unveiled data from the Disrupt PAD III study, which showed IVL to be superior to percutaneous transluminal angioplasty on the primary endpoint of procedural success.

Children with arthritis affecting five or more joints, called polyarticular juvenile idiopathic arthritis, living in less affluent families were twice as likely to report more than an hour of morning joint stiffness, compared to their counterparts from more affluent families, according to a study by investigators at Hospital for Special Surgery.